Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Lumasiran · Oxlumo, OXLUMO

Oligonucleotide (siRNA) · Gene silencing: hydroxyacid oxidase 1 (glycolate oxidase) (HAO1) · developed by Alnylam Pharms

Approved FDA, Nov 2020

ALNY Developer

1 Registered trials

What is Lumasiran?

Lumasiran is a small interfering RNA that acts in hepatocytes through RNA interference to degrade HAO1 messenger RNA, lowering glycolate oxidase enzyme levels and thereby reducing glyoxylate available for oxalate production. It is studied in primary hyperoxaluria type 1 and primary hyperoxaluria.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Oxlumo, OXLUMO, ALN-GO1
Drug type: Oligonucleotide (siRNA)
Targets: hydroxyacid oxidase 1 (glycolate oxidase) (HAO1)
Mechanism: Gene silencing: hydroxyacid oxidase 1 (glycolate oxidase) (HAO1)
Pathways: glyoxylate metabolism, oxalate production
Therapy area: Metabolic, Renal & urology
Developer: Alnylam Pharms Inc (ALNY)
FDA status: Approved as Oxlumo (November 23, 2020), NDA214103 · FDA label
UNII: 67P6XH37HD

✅ FDA-approved uses

Primary hyperoxaluria type 1 (PH1)

From the indications section of the FDA label (version of Dec 1, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04152200	Phase 3	Primary Hyperoxaluria Type 1	Completed	ALNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Primary HyperoxaluriaPrimary Hyperoxaluria Type 1

More from Alnylam Pharms

Givosiran FDA approved Patisiran FDA approved Vutrisiran FDA approved ALN-2232 Phase 1/2 ALN-4285 Phase 1 ALN-4324 Phase 2 ALN-4915 Phase 1 ALN-5288 Phase 1 ALN-6222 Phase 1 ALN-6400 Phase 1/2 ALN-AGT01 RVR Phase 2 ALN-BCAT Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALNY page.

Follow ALNY, the company behind Lumasiran

See ALNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALNY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z